Aligos Therapeutics Inc.

NASDAQ: ALGS · Real-Time Price · USD
7.58
-0.07 (-0.92%)
At close: Aug 14, 2025, 3:59 PM
7.60
0.20%
Pre-market: Aug 15, 2025, 08:27 AM EDT

Aligos Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
3.94M 15.53M 13.91M 4.36M
Cost of Revenue
n/a 3.07M 3.67M 104.15M
Gross Profit
3.94M 12.46M 10.23M -99.79M
Operating Income
-89.15M -88.13M -97.58M -128.32M
Interest Income
n/a 1.24M 1.64M 132K
Pretax Income
-130.88M -86.88M -95.94M -128.19M
Net Income
-131.21M -87.68M -96.05M -128.33M
Selling & General & Admin
22.83M 30.62M 26.41M 28.53M
Research & Development
70.27M 73.04M 85.08M 104.15M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
93.1M 103.66M 111.49M 132.68M
Interest Expense
n/a n/a 1.64M 132K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
93.1M 102.96M 111.49M 132.68M
Income Tax Expense
331K 795K 106K 143K
Shares Outstanding (Basic)
6.26M 24.87M 42.7M 39.86M
Shares Outstanding (Diluted)
6.26M 24.87M 42.7M 39.86M
EPS (Basic)
-20.94 -3.52 -2.25 -3.22
EPS (Diluted)
-20.94 -3.52 -2.25 -3.22
EBITDA
-89.15M -85.06M -93.91M -124.54M
EBIT
-89.15M -88.13M -97.58M -128.32M
Depreciation & Amortization
n/a 3.07M 3.67M 3.78M